Report cover image

Global Infectious Disease Therapeutics Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Feb 06, 2024
Length 180 Pages
SKU # EMAR18558235

Description

Global Infectious Disease Therapeutics Market Report and Forecast 2024-2032


Global Infectious Disease Therapeutics Market Report and Forecast 2024-2032

Global Infectious Disease Therapeutics Market Outlook

The global infectious disease therapeutics market size was valued at USD 109.8 billion in 2023, driven by increasing prevalence of antimicrobial-resistant pathogens across the globe. The market size is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032 to achieve a value of USD 189.7 billion by 2032.

Infectious Disease Therapeutics: Introduction

Infectious disease therapeutics refers to the treatment and management of diseases caused by pathogens such as bacteria, viruses, fungi, or parasites. This field encompasses a wide range of medications, including antibiotics, antivirals, antifungals, and antiparasitics, tailored to target specific infectious agents. The choice of therapy depends on the type of pathogen, its resistance patterns, and the patient's health status. Recent advances include the development of novel drugs, vaccines, and combination therapies to combat drug-resistant strains and emerging infectious diseases.

Key Trends in the Global Infectious Disease Therapeutics Market

One of the most pressing trends is the increasing prevalence of antimicrobial-resistant pathogens, which is driving research and development efforts to discover new antimicrobial agents and alternative therapies.

Recent years have seen significant progress in vaccine technology, including mRNA vaccines, which offer rapid development opportunities for infectious diseases, as evidenced by the COVID-19 pandemic response.

There's a growing interest in developing combination therapies that use more than one drug to treat infectious diseases, aiming to enhance efficacy and prevent the development of resistance.

The emergence of new pathogens and re-emergence of old ones, such as Ebola and Zika, have highlighted the need for continuous surveillance, rapid diagnostic methods, and the development of flexible therapeutic platforms.

The market is seeing a shift towards personalized medicine approaches, where treatments are tailored based on individual patient profiles and specific pathogen characteristics, guided by advanced diagnostics.

The integration of point-of-care diagnostic tools is becoming more prevalent, allowing for quicker diagnosis and the initiation of targeted therapies, improving patient outcomes.

International collaborations and funding initiatives are crucial in combating infectious diseases, especially in low- and middle-income countries. These efforts focus on vaccine distribution, improving access to treatments, and strengthening healthcare systems.

Digital tools and telemedicine are increasingly used for monitoring infectious disease outbreaks, improving treatment adherence, and managing patient care remotely, especially in regions with limited healthcare access.

Global Infectious Disease Therapeutics Market Segmentation

Market Breakup by Disease
  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Tuberculosis
  • Malaria
  • Others
Market Breakup by Infection Type
  • Bacterial
  • Viral
  • Fungal
  • Parasitic
  • Others
Market Breakup by Treatment Type
  • Drugs
  • Vaccines
Market Breakup by Mode of Treatment
  • Oral
  • Parenteral
  • Topical
  • Others
Market Breakup by Distribution Channel
  • Hospitals
  • Clinics
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Global Infectious Disease Therapeutics Market Overview

In North America, the infectious disease therapeutics market is characterized by advanced healthcare infrastructure and a strong focus on research and development. The region sees significant investment in the development of new antibiotics and antivirals, particularly to address drug-resistant infections and emerging diseases like COVID-19. There's also a growing emphasis on vaccination programs and the adoption of combination therapies to enhance treatment efficacy.

Europe's market benefits from robust public health systems and coordinated efforts across countries to manage infectious diseases. The region focuses on antimicrobial stewardship to combat antibiotic resistance and supports the development of novel therapeutics through regulatory incentives. Collaboration between the European Union members for vaccine procurement and distribution, especially for pandemic preparedness, is a key trend.

The Asia-Pacific region exhibits rapid growth in the infectious disease therapeutics market, driven by increasing healthcare expenditure and a high burden of infectious diseases. Countries like China and India are significant contributors to the market, focusing on both the production of generic medications and the development of new treatments. Efforts to improve healthcare access and the rising demand for vaccines and advanced therapies contribute to market dynamics.

Global Infectious Disease Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Merck & Co.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca Plc
  • Mylan N.V.
  • Novartis AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma
  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • Gilead Sciences
  • Johnson & Johnson
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

180 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Infectious Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Infectious Disease Epidemiology Analysis
5.1 Global Infectious Disease Epidemiology Scenario Overview (2017-2032)
5.2 North America Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.3 Europe Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.4 Asia Pacific Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.5 Latin America Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
5.6 Middle East & Africa Infectious Disease Epidemiology Scenario and Forecast (2017-2032)
6 Global Infectious Disease Therapeutics Market Overview
6.1 Global Infectious Disease Therapeutics Market Historical Value (2017-2023)
6.2 Global Infectious Disease Therapeutics Market Forecast Value (2024-2032)
7 Global Infectious Disease Therapeutics Market Landscape*
7.1 Global Infectious Disease Therapeutics Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Infectious Disease Therapeutics Product Landscape
7.2.1 Analysis by Mode of Treatment
7.2.2 Analysis by Infection Type
7.2.3 Analysis by Indication
8 Infectious Disease Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Infectious Disease Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Infectious Disease Therapeutics Market Segmentation (2017-2032)
11.1 Global Infectious Disease Therapeutics Market (2017-2032) by Disease
11.1.1 Market Overview
11.1.2 HIV/AIDS
11.1.3 Influenza
11.1.4 Hepatitis
11.1.5 Tuberculosis
11.1.6 Malaria
11.1.7 Others
11.2 Global Infectious Disease Therapeutics Market (2017-2032) by Infection Type
11.2.1 Market Overview
11.2.2 Bacterial
11.2.3 Viral
11.2.4 Fungal
11.2.5 Parasitic
11.2.6 Others
11.3 Global Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
11.3.1 Market Overview
11.3.2 Drugs
11.3.3 Vaccines
11.4 Global Infectious Disease Therapeutics Market (2017-2032) by Mode of Treatment
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Topical
11.4.5 Others
11.5 Global Infectious Disease Therapeutics Market (2017-2032) by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Clinics
11.5.4 Others
11.6 Global Infectious Disease Therapeutics Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Infectious Disease Therapeutics Market
12.1 North America Infectious Disease Therapeutics Market (2017-2032) by Disease
12.1.1 Market Overview
12.1.2 HIV/AIDS
12.1.3 Influenza
12.1.4 Hepatitis
12.1.5 Tuberculosis
12.1.6 Malaria
12.1.7 Others
12.2 North America Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
12.2.1 Market Overview
12.2.2 Drugs
12.2.3 Vaccines
12.3 North America Infectious Disease Therapeutics Market (2017-2032) by Country
12.3.1 United States of America
12.3.2 Canada
13 Europe Infectious Disease Therapeutics Market
13.1 Europe Infectious Disease Therapeutics Market (2017-2032) by Disease
13.1.1 Market Overview
13.1.2 HIV/AIDS
13.1.3 Influenza
13.1.4 Hepatitis
13.1.5 Tuberculosis
13.1.6 Malaria
13.1.7 Others
13.2 Europe Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
13.2.1 Market Overview
13.2.2 Drugs
13.2.3 Vaccines
13.3 Europe Infectious Disease Therapeutics Market (2017-2032) by Country
13.3.1 United Kingdom
13.3.2 Germany
13.3.3 France
13.3.4 Italy
13.3.5 Others
14 Asia Pacific Infectious Disease Therapeutics Market
14.1 Asia Pacific Infectious Disease Therapeutics Market (2017-2032) by Disease
14.1.1 Market Overview
14.1.2 HIV/AIDS
14.1.3 Influenza
14.1.4 Hepatitis
14.1.5 Tuberculosis
14.1.6 Malaria
14.1.7 Others
14.2 Asia Pacific Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
14.2.1 Market Overview
14.2.2 Drugs
14.2.3 Vaccines
14.3 Asia Pacific Infectious Disease Therapeutics Market (2017-2032) by Country
14.3.1 China
14.3.2 Japan
14.3.3 India
14.3.4 ASEAN
14.3.5 Australia
14.3.6 Others
15 Latin America Infectious Disease Therapeutics Market
15.1 Latin America Infectious Disease Therapeutics Market (2017-2032) by Disease
15.1.1 Market Overview
15.1.2 HIV/AIDS
15.1.3 Influenza
15.1.4 Hepatitis
15.1.5 Tuberculosis
15.1.6 Malaria
15.1.7 Others
15.2 Latin America Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
15.2.1 Market Overview
15.2.2 Drugs
15.2.3 Vaccines
15.3 Latin America Infectious Disease Therapeutics Market (2017-2032) by Country
15.3.1 Brazil
15.3.2 Argentina
15.3.3 Mexico
15.3.4 Others
16 Middle East and Africa Infectious Disease Therapeutics Market
16.1 Middle East and Africa Infectious Disease Therapeutics Market (2017-2032) by Disease
16.1.1 Market Overview
16.1.2 HIV/AIDS
16.1.3 Influenza
16.1.4 Hepatitis
16.1.5 Tuberculosis
16.1.6 Malaria
16.1.7 Others
16.2 Middle East and Africa Infectious Disease Therapeutics Market (2017-2032) by Treatment Type
16.2.1 Market Overview
16.2.2 Drugs
16.2.3 Vaccines
16.3 Middle East and Africa Infectious Disease Therapeutics Market (2017-2032) by Country
16.3.1 Saudi Arabia
16.3.2 United Arab Emirates
16.3.3 Nigeria
16.3.4 South Africa
16.3.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Pfizer Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 GlaxoSmithKline plc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Merck & Co.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 F. Hoffmann-La Roche Ltd.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 AstraZeneca Plc
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Mylan N.V.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Novartis AG
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Sanofi SA
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Takeda Pharmaceutical Company Limited
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Astellas Pharma
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 AbbVie Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Boehringer Ingelheim GmbH
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Gilead Sciences
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Johnson & Johnson
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
List not exhaustive
23 Global Infectious Disease Therapeutics Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us